To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
argenx Partnered Programs
When our Immunology Innovation Program (IIP) produces assets outside our core focus, we pull in the right partners to push them forward. That’s co-creation in practice. Good science should reach patients. We give it every chance to do so.
Proven Immunology Innovation Program Impact
argenx has several assets that emerged from the Immunology Innovation Program that have been out-licensed to a partner for further development.
Target: IL-22R
LEO Pharma is a global pharmaceutical company specializing in dermatology. ARGX-112 (LP0145) was designed as a SIMPLE AntibodyTM to block IL22R, a receptor that drives inflammatory activity in the skin. LEO Pharma is evaluating this antibody as a potential treatment for atopic dermatitis.
Target: MET
Agomab Therapeutics is a biotechnology company focused on regenerative medicine. ARGX-114 (now AGMB-101) was developed from argenx’s SIMPLE AntibodyTM platform to target the MET receptor, which plays a vital role in tissue repair and regeneration. Agomab is advancing this antibody as a potential therapy for patients living with fibrotic, inflammatory, autoimmune, and degenerative diseases.
Target: GARP
AbbVie is a global biopharmaceutical company with expertise spanning oncology, immunology, and neuroscience. ARGX-115 (now ABBV-151) is a SIMPLE AntibodyTM designed to block GARP, a protein that enables tumors to suppress immune responses. AbbVie is investigating this antibody for its potential to reactivate the immune system against cancer.
Externally Sponsored Research
We believe in accelerating discovery processes to bring solutions to patients through innovative and collaborative science-driven research.
Externally Sponsored Research (ESR) can lead to meaningful advances in disease understanding and treatment.
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
ARGX-118
Designed around the first novel airway inflammation target identified in decades.
Empasiprubart
Engineered to block complement activation at C2, with potential across multiple severe disease indications.
Efgartigimod
The science and data behind our first-in-class FcRn-targeting antibody for severe autoimmune diseases.
